Compare SBFG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBFG | ADCT |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.8M | 136.1M |
| IPO Year | 2014 | 2019 |
| Metric | SBFG | ADCT |
|---|---|---|
| Price | $26.88 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 62.8K | ★ 1.5M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | 27.33 | ★ 30.86 |
| EPS | ★ 0.69 | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.49 |
| P/E Ratio | $39.07 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $18.16 | $0.78 |
| 52 Week High | $27.69 | $4.98 |
| Indicator | SBFG | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 67.71 | 40.09 |
| Support Level | $20.94 | $0.78 |
| Resistance Level | N/A | $1.44 |
| Average True Range (ATR) | 0.99 | 0.11 |
| MACD | 0.09 | 0.08 |
| Stochastic Oscillator | 85.11 | 60.67 |
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).